New Research Core for Precision Medicine
German Federal Ministry of Education and Research to provide approx. 5.7 million euros for new Berlin consortium “MSTARS”
News from Feb 10, 2020
Berlin’s research leaders are pooling their expertise in mass spectrometry for precision medicine. The German Federal Ministry of Education and Research (BMBF) will provide approximately 5.7 million euros in funding for a minimum of three years for a new consortium, MSTARS (Multimodal clinical mass spectrometry to target treatment resistance.)
The aim of the consortium is to further develop current technology in mass spectrometry to better understand the interplay of disease-relevant cell components and, by doing so, improve precision medicine, i.e. the ability to tailor treatments to the individual patient. The consortium consisting of research groups from Charité – Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine (MDC) cooperates with research partners from Humboldt-Universität zu Berlin, Berlin Institute of Health (BIH), and the Max Planck Institute for Molecular Genetics.
The four coordinators of the MSTARS consortium are Prof. Dr. Matthias Selbach, Group Leader of MDC’s Proteome Dynamics Lab, and three researchers from Charité: Prof. Dr. Ulrich Keilholz, Director of the Charité Comprehensive Cancer Center; Prof. Dr. Markus Ralser, Director of Charité’s Institute of Biochemistry, and Prof. Dr. Frederick Klauschen of Charité’s Institute of Pathology.
The MSTARS project is being funded under a special BMBF funding program, which focuses on establishing research cores dedicated to mass spectrometry in systems medicine. MSTARS is one of a total of four such BMBF-funded research consortia. The projects will be launched on March 1, 2020.